Open Access

Individualized therapy based on the combination of mini‑PDX and NGS for a patient with metastatic AFP‑producing and HER‑2 amplified gastric cancer

  • Authors:
    • Xiaodan Zhu
    • Xiaoqing Xu
    • Baonan Zhang
    • Yun Dong
    • Shixia Gong
    • Tingjie Gong
    • Feifei Zhang
    • Chunhui Jin
  • View Affiliations

  • Published online on: September 27, 2022     https://doi.org/10.3892/ol.2022.13531
  • Article Number: 411
  • Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Mini‑patient‑derived xenograft (mini‑PDX) is a novel, rapid and accurate method used to assess in vivo drug susceptibility. In the present study, a mini‑PDX combined with next‑generation sequencing (NGS) was used to guide the individualized treatment of a patient with metastatic a‑fetoprotein‑producing and human epidermal growth factor receptor 2 (HER‑2) amplified gastric cancer (GC). Tumor cells were isolated from the tumor tissue obtained from gastroscopic biopsy, transferred into capsules and implanted into severe combined immunodeficiency mice to determine their sensitivity to various drug regimens. NGS was also performed to assess the mutation spectrum of the cells. The results were analyzed to select the most appropriate treatment regimen for the patient. The mini‑PDX model confirmed that the patient's tumor was sensitive to a combination regimen of irinotecan and tegafur‑gimeracil‑oteracil (S‑1). Fluorescence in situ hybridization assay of the tumor tissue confirmed HER‑2 amplification. The NGS results indicated ERBB2 amplification, and tumor protein P53 [c.659A>G (p.Y220C)], ataxia‑telengiectasia mutated [c.125A>G (p.H42R)] and MutS homolog 6 [c.3254C(8>7) (p.F1088Sfs*2)] mutation, in which UGT1A1*28, TA6/7 (rs8175347) was a mutant heterozygote. After six courses of treatment with a regimen comprising 300 mg irinotecan on day 1 + 40 mg S‑1 twice daily on days 2‑15 + 350 mg trastuzumab once‑every 3 weeks, the patient continued with S‑1 treatment for 4 courses and trastuzumab for 1 year. The patient retained progression‑free survival status at the 32‑month follow‑up. Thus, the mini‑PDX model combined with the NGS rapidly assessed drug sensitivity in a patient with GC and revealed key genetic mutations. However, the proposed technique requires further research to confirm its potential in the individualized treatment of patients with refractory malignancies.
View Figures
View References

Related Articles

Journal Cover

November-2022
Volume 24 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhu X, Xu X, Zhang B, Dong Y, Gong S, Gong T, Zhang F and Jin C: Individualized therapy based on the combination of mini‑PDX and NGS for a patient with metastatic AFP‑producing and HER‑2 amplified gastric cancer. Oncol Lett 24: 411, 2022
APA
Zhu, X., Xu, X., Zhang, B., Dong, Y., Gong, S., Gong, T. ... Jin, C. (2022). Individualized therapy based on the combination of mini‑PDX and NGS for a patient with metastatic AFP‑producing and HER‑2 amplified gastric cancer. Oncology Letters, 24, 411. https://doi.org/10.3892/ol.2022.13531
MLA
Zhu, X., Xu, X., Zhang, B., Dong, Y., Gong, S., Gong, T., Zhang, F., Jin, C."Individualized therapy based on the combination of mini‑PDX and NGS for a patient with metastatic AFP‑producing and HER‑2 amplified gastric cancer". Oncology Letters 24.5 (2022): 411.
Chicago
Zhu, X., Xu, X., Zhang, B., Dong, Y., Gong, S., Gong, T., Zhang, F., Jin, C."Individualized therapy based on the combination of mini‑PDX and NGS for a patient with metastatic AFP‑producing and HER‑2 amplified gastric cancer". Oncology Letters 24, no. 5 (2022): 411. https://doi.org/10.3892/ol.2022.13531